Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.
about
P1343
The role of Src in solid tumorsClinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancerProliferating cell nuclear antigen is protected from degradation by forming a complex with MutT Homolog2Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasisPhase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAsA phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer.Antivascular therapy for epithelial ovarian cancer.Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.Prediction and testing of biological networks underlying intestinal cancerThe role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cellsA Phosphotyrosine Proteomic Screen Identifies Multiple Tyrosine Kinase Signaling Pathways Aberrantly Activated in Malignant Mesothelioma.Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells.Functional roles of Src and Fgr in ovarian carcinoma.The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy.Dopamine blocks stress-mediated ovarian carcinoma growth.Src family kinases and paclitaxel sensitivity.Therapeutic advances in women's cancersMicroenvironment and pathogenesis of epithelial ovarian cancerClinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions.Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies.Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling.Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumoursThe adhesion molecule NCAM promotes ovarian cancer progression via FGFR signallingTargeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma.Integrating biologically targeted therapy in head and neck squamous cell carcinomasNetwork analysis identifies an HSP90-central hub susceptible in ovarian cancerDasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis.Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression.Current treatment and clinical trials in ovarian cancer.Molecular targeted therapy in ovarian cancer: what is on the horizon?Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales.Characterisation of in vivo ovarian cancer models by quantitative 1H magnetic resonance spectroscopy and diffusion-weighted imaging.Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancersPhosphorylation of caspase-9 at Thr125 directs paclitaxel resistance in ovarian cancer.Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer.
P2860
Q24616659-FACA9FFC-5FD6-4CDD-9D32-70B36F4EC3B7Q27024235-3D702834-FD1F-4646-8BF5-C9403BDEE1FFQ28118092-E99D1899-CC78-438E-B188-9D346081CBF4Q28307739-49BECD39-4425-45E1-B668-D7DDCE93390FQ30416923-8EC619C0-9A90-4BB8-961F-7C7EFB54A973Q30844815-98EFA9F8-AD70-4FCF-A670-1BB67F850E2EQ33402553-DC7C7691-E3D7-4691-81E6-30B63479DC42Q33583598-C36F491B-8C7A-4366-8B15-9015BA490171Q33604480-AA7D7E1D-36AD-4282-90FC-6F951C32800CQ33687092-FE4B3F7B-744A-4DF8-A3BC-F4D598799DCEQ33980966-C4305E1D-EDB9-40B6-9EA4-4EBC132FA673Q34018570-94233544-B839-4987-8B8A-FD92EC2EEF24Q34708878-6CB4AE5E-B39F-414D-9095-A62355F9D5F0Q34796603-D848D104-B463-4744-97A6-80CE0D62BB12Q34966503-CE4ADF04-5CD7-4322-9E6B-D688D473BEB3Q35023940-74B69B15-C62B-4A78-998F-3F1259F81C0FQ35214722-09C8D4A3-652D-4823-B67A-9838C3AF3A90Q35418973-96D5C530-0932-4955-B234-5FC113CA6CD7Q35419057-6C1669B5-F383-49C2-8D31-5B78828D0FC6Q35575176-F4920A04-6A4B-4205-B265-02A03C625542Q35750289-6688D2E5-84D4-4AFA-80DF-767856C77C2EQ35919774-04BAACE4-6C55-4789-8EE1-75286D68193CQ35998482-90BAB8F6-8C99-442B-835C-BCB2CA73FF1EQ36038778-9D72F781-CE5E-47D5-B79D-6E05D9145489Q36916923-3400CAFC-431F-42B9-A515-AA26E811D5F9Q37081427-0160DC27-8D19-432D-AF34-60031A429534Q37185385-C5B635A5-E156-4FCA-AE88-02473399CEAEQ37287442-ADB665F6-4346-49E1-89D7-611FAA8E5FB2Q37398815-1035A4A4-691B-4B93-8480-24B0C97A8D23Q37401245-344EFC00-7249-450B-9627-51EF9BFA0EB7Q37405207-C0271CFE-CCAC-438C-A8E7-7F6D4ABF37C0Q37625252-EB12D2D9-0EF8-433A-9C44-6F7FDEABC44AQ37724199-547A847D-5C94-464C-917E-8F69A32EA8C2Q37888659-F624EF8A-DA36-4F0D-9432-90FAAFF329B5Q38130312-5528E452-631D-4363-B8AE-EDD4D9B1ED07Q39454124-54173F70-59E3-46AA-8A33-274824CC4C0CQ39507461-128CCBE7-B015-4660-9AF6-B899A188695DQ41305086-F613E232-A604-4FE4-B623-0A427177CBE0Q48507362-F996FD66-7445-48E2-A681-8F3EE9C703C8Q50005441-2BFF9698-512C-43F7-B1F7-7CBBB30D6CFA
P2860
Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.
@ast
Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.
@en
type
label
Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.
@ast
Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.
@en
prefLabel
Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.
@ast
Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.
@en
P2093
P2860
P1433
P1476
Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.
@en
P2093
Anil K Sood
Aparna A Kamat
Charles N Landen
Chester A Metcalf
David C Dalgarno
David M Gershenson
Gary E Gallick
Jose G Trevino
Jyotsnabaran Halder
P2860
P304
P356
10.1158/0008-5472.CAN-06-1410
P407
P4510
P577
2006-09-01T00:00:00Z